Myriam Ben-Arush
Overview
Explore the profile of Myriam Ben-Arush including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
284
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bisogno G, Chisholm J, Hladun R, De Salvo G, Guerin F, Casanova M, et al.
J Clin Oncol
. 2025 Mar;
:JCO2402850.
PMID: 40053891
The European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) RMS 2005 trial evaluated maintenance chemotherapy in high-risk rhabdomyosarcoma (RMS). Patients were randomly assigned to either discontinue treatment (standard arm) or...
2.
Mandeville H, Bisogno G, Minard-Colin V, Alaggio R, Ben-Arush M, Chargari C, et al.
Cancer
. 2025 Feb;
131(4):e35744.
PMID: 39916392
No abstract available.
3.
Feldman T, Vlodavsky E, Sarji S, Abu El Hija A, Benifla M, Oren L, et al.
Int J Surg Pathol
. 2025 Jan;
:10668969241311520.
PMID: 39887183
The combination of ependymoma and gliosarcoma elements in the same tumor is extremely rare, and the molecular characteristics of these entities are not clear. Here, we present a rare aggressive...
4.
Schoot R, Taselaar P, Scarzello G, Kolb F, Coppadoro B, Horst S, et al.
Head Neck
. 2024 Nov;
47(3):974-982.
PMID: 39545397
Background: Parameningeal (PM) site is an unfavorable characteristic in rhabdomyosarcoma (RMS). We described the treatment and outcome for patients with PM RMS and investigated the prognostic value of risk factors....
5.
Gressel O, Ofir R, Ash S, Ben-Arush M, Samuels N, Ben-Arye E
J Pain Symptom Manage
. 2024 Sep;
68(6):e508-e515.
PMID: 39218124
Background: Parents of children with cancer face bio-psycho-social-spiritual concerns which can significantly reduce quality of life (QoL). We examined the impact of an integrative oncology (IO) intervention on QoL-related concerns...
6.
Mandeville H, Bisogno G, Minard-Colin V, Alaggio R, Ben-Arush M, Chargari C, et al.
Cancer
. 2024 Jul;
130(23):4071-4084.
PMID: 39058728
Background: The authors report the prospective evaluation of reduced dose alkylator chemotherapy combined with radiotherapy for European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) standard risk nonalveolar rhabdomyosarcoma (NA-RMS). Patients...
7.
Kolodziejczak A, Guerrini-Rousseau L, Planchon J, Ecker J, Selt F, Mynarek M, et al.
Neuro Oncol
. 2023 Jun;
25(12):2273-2286.
PMID: 37379234
Background: The prognosis for Li-Fraumeni syndrome (LFS) patients with medulloblastoma (MB) is poor. Comprehensive clinical data for this patient group is lacking, challenging the development of novel therapeutic strategies. Here,...
8.
Bisogno G, Minard-Colin V, Zanetti I, Ferrari A, Gallego S, Davila Fajardo R, et al.
J Clin Oncol
. 2023 Feb;
41(13):2342-2349.
PMID: 36848614
JCO The RMS2005 study included two phase III randomized trials for high-risk (HR) and observational trials for low (LR), standard (SR), and very high-risk (VHR) patients who have been partially...
9.
Ben-Arush M, Minard-Colin V, Scarzello G, Fajardo R, Terwisscha van Scheltinga S, Bernier V, et al.
Eur J Cancer
. 2022 Jun;
172:119-129.
PMID: 35763871
Purpose: Regional lymph node disease (N1) is a component of the risk-based treatment stratification in rhabdomyosarcoma (RMS). The purpose of this study was to determine the contribution of nodal disease...
10.
Schoot R, Chisholm J, Casanova M, Minard-Colin V, Geoerger B, Cameron A, et al.
J Clin Oncol
. 2022 Jun;
40(32):3730-3740.
PMID: 35709412
Purpose: Outcome for patients with metastatic rhabdomyosarcoma (RMS) is poor. This study presents the results of the MTS 2008 study with a pooled analysis including patients from the concurrent BERNIE...